BostonGene Receives Frost & Sullivan's 2026 Global Company of the Year for Advancing in AI-Driven Multimodal Oncology Platforms
Recognition highlights BostonGene's leadership in improving drug development decisions, reducing risk and accelerating patient impact SAN ANTONIO, May 5, 2026 /PRNewswire/ -- Frost & Sullivan is pleased to announce that BostonGene has been...
BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions
Reshaping the Global Drug Development Landscape with the Industry's Only Natively AI-Powered Omnimodal Foundation Model for Tumor and Immune Biology SAN ANTONIO, Jan. 12, 2026 /PRNewswire/ -- Frost & Sullivan is pleased to announce that...